Massari, F. et al. Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. Clin. Genitourin. Cancer 11, 471–476 (2013).

Article  PubMed  Google Scholar 

Ravaud, A. et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N. Engl. J. Med. 375, 2246–2254 (2016).

Article  CAS  PubMed  Google Scholar 

Choueiri, T. K. et al. Overall survival with adjuvant pembrolizumab in renal-cell carcinoma. N. Engl. J. Med. 390, 1359–1371 (2024).

Article  CAS  PubMed  Google Scholar 

Mollica, V. & Massari, F. Adjuvant treatment in renal cell carcinoma: a never-ending story? Lancet 403, 433–434 (2024).

Article  CAS  PubMed  Google Scholar 

Rosellini, M. et al. Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. Nat. Rev. Urol. 20, 133–157 (2023).

Article  CAS  PubMed  Google Scholar 

Barragan-Carrillo, R., Govindarajan, A., Rock, A., Sperandio, R. C. & Pal, S. K. Managing metastatic renal cell carcinoma after progression on immunotherapy. Hematol. Oncol. Clin. North Am. 37, 965–976 (2023).

Article  PubMed  Google Scholar 

Bourlon, M. T., Valdez, P., Choueiri, T. K. & Lam, E. Using clinical characteristics to guide treatment of recurrent RCC after adjuvant pembrolizumab. ASCO Daily News https://dailynews.ascopubs.org/do/using-clinical-characteristics-guide-treatment-recurrent-rcc-after-adjuvant (2024).

Kluger, H. M. et al. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. J. Immunother. Cancer 8, e000398 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Rosellini, M., Tassinari, E., Marchetti, A., Mollica, V. & Massari, F. Re: atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. Eur. Urol. 85, 97–98 (2024).

Article  CAS  PubMed  Google Scholar 

Choueiri, T. K. et al. Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study. Lancet Oncol. 24, 553–562 (2023).

Article  CAS  PubMed  Google Scholar